These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 1670617)
21. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. Krystal JH; Seibyl JP; Price LH; Woods SW; Heninger GR; Aghajanian GK; Charney DS Arch Gen Psychiatry; 1993 Aug; 50(8):624-35. PubMed ID: 8102048 [TBL] [Abstract][Full Text] [Related]
22. Adjunctive carbamazepine or lithium carbonate in therapy-resistant chronic schizophrenia. Simhandl C; Meszaros K; Denk E; Thau K; Topitz A Can J Psychiatry; 1996 Jun; 41(5):317. PubMed ID: 8793154 [No Abstract] [Full Text] [Related]
23. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Evins AE; Fitzgerald SM; Wine L; Rosselli R; Goff DC Am J Psychiatry; 2000 May; 157(5):826-8. PubMed ID: 10784481 [TBL] [Abstract][Full Text] [Related]
24. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Potkin SG; Jin Y; Bunney BG; Costa J; Gulasekaram B Am J Psychiatry; 1999 Jan; 156(1):145-7. PubMed ID: 9892314 [TBL] [Abstract][Full Text] [Related]
25. A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse. Steingard S; Allen M; Schooler NR J Clin Psychiatry; 1994 Nov; 55(11):470-2. PubMed ID: 7989278 [TBL] [Abstract][Full Text] [Related]
31. Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics. Prosser ES; Csernansky JG; Kaplan J; Thiemann S; Becker TJ; Hollister LE J Nerv Ment Dis; 1987 Feb; 175(2):100-5. PubMed ID: 2879880 [TBL] [Abstract][Full Text] [Related]
32. Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. Gardner DL; Cowdry RW Am J Psychiatry; 1986 Apr; 143(4):519-22. PubMed ID: 3513634 [TBL] [Abstract][Full Text] [Related]
33. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. Remington G; Seeman P; Feingold A; Mann S; Shammi C; Kapur S J Clin Psychiatry; 2011 Aug; 72(8):1042-8. PubMed ID: 20868639 [TBL] [Abstract][Full Text] [Related]
34. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics. Gleason RP; Schneider LS J Clin Psychiatry; 1990 Mar; 51(3):115-8. PubMed ID: 1968457 [TBL] [Abstract][Full Text] [Related]
35. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. Kinon BJ; Basson BR; Gilmore JA; Malcolm S; Stauffer VL J Clin Psychiatry; 2000 Nov; 61(11):833-40. PubMed ID: 11105736 [TBL] [Abstract][Full Text] [Related]
36. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Olin JT; Fox LS; Pawluczyk S; Taggart NA; Schneider LS Am J Geriatr Psychiatry; 2001; 9(4):400-5. PubMed ID: 11739066 [TBL] [Abstract][Full Text] [Related]
37. Recent psychostimulant use in hospitalized schizophrenics. Richard ML; Liskow BI; Perry PJ J Clin Psychiatry; 1985 Mar; 46(3):79-83. PubMed ID: 2857708 [TBL] [Abstract][Full Text] [Related]
38. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Kane JM; Rifkin A; Woerner M; Reardon G; Sarantakos S; Schiebel D; Ramos-Lorenzi J Arch Gen Psychiatry; 1983 Aug; 40(8):893-6. PubMed ID: 6347119 [TBL] [Abstract][Full Text] [Related]
39. A one year prospective study of the effect of life events and medication in the aetiology of schizophrenic relapse. Hirsch S; Bowen J; Emami J; Cramer P; Jolley A; Haw C; Dickinson M Br J Psychiatry; 1996 Jan; 168(1):49-56. PubMed ID: 8770428 [TBL] [Abstract][Full Text] [Related]
40. Low dose medication strategies in the maintenance treatment of schizophrenia. Kane JM Schizophr Bull; 1983; 9(4):528-32. PubMed ID: 6140751 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]